Lineage Cell Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders' Equity
| Three Months Ended March 31, 2026 | ||||||
|---|---|---|---|---|---|---|
| Accumulated | ||||||
| Other · Total | ||||||
| Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - December 31, 2025 | 243,122 | $515,467 | $(466,998) | $(1,203) | $(3,920) | $43,346 |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 44 | (40) | — | — | — | (40) |
| Shares issued upon exercise of stock options | 211 | 227 | — | — | — | 227 |
| Shares issued upon exercise of warrants | 5,921 | 5,388 | — | — | — | 5,388 |
| Derivative warrant liability reclassified to share capital on exercise of warrants | — | 7,442 | — | — | — | 7,442 |
| Stock-based compensation | — | 1,172 | — | — | — | 1,172 |
| Unrealized loss on marketable debt securities | — | — | — | — | (9) | (9) |
| Foreign currency translation adjustment | — | — | — | — | (42) | (42) |
| Net income (loss) | — | — | (4,812) | 23 | — | (4,789) |
| BALANCE - March 31, 2026 | 249,298 | $529,656 | $(471,810) | $(1,180) | $(3,971) | $52,695 |
| Three Months Ended March 31, 2025 | ||||||
|---|---|---|---|---|---|---|
| Accumulated | ||||||
| Other · Total | ||||||
| Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - December 31, 2024 | 220,416 | $484,722 | $(403,465) | $(1,369) | $(2,876) | $77,012 |
| Shares issued through registered direct financing | 7,895 | 3,795 | — | — | — | 3,795 |
| Financing related fees | — | (406) | — | — | — | (406) |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 45 | (15) | — | — | — | (15) |
| Stock-based compensation | — | 1,217 | — | — | — | 1,217 |
| Unrealized loss on marketable debt securities | — | — | — | — | (5) | (5) |
| Foreign currency translation adjustment | — | — | — | — | 200 | 200 |
| Net income (loss) | — | — | (4,139) | (4) | — | (4,143) |
| BALANCE - March 31, 2025 | 228,356 | $489,313 | $(407,604) | $(1,373) | $(2,681) | $77,655 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.